• Explore /
  • Poster
  • / SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Abstract Poster

Authors

null

David Bing Zhen

University of Washington/Fred Hutchison Cancer Research Center, Seattle, WA

David Bing Zhen , Edward Mayerson , E. Gabriela Chiorean , Earle F Burgess , Elizabeth M. Swisher , Carl Michael Gay , Lauren Averett Byers , Ignacio Ivan Wistuba , Haider Mahdi , Satya Das , Jason S. Starr , Megan Othus , Young Kwang Chae , Razelle Kurzrock

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT05058651

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4179)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4179

Abstract #

TPS4179

Poster Bd #

155a

Abstract Disclosures

Similar Posters

First Author: David Bing Zhen

First Author: Tiandong Kong

First Author: Ana Oaknin

First Author: Gerard Zalcman